Chemcon Speciality Chemicals Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹55Cr
- −7.9% YoY
- +0.9% QoQ
- Net profit
- ₹4Cr
- +36.2% YoY
- −55.2% QoQ
- Margin
- 10.55%
- +3.2 pp YoY
- −10.2 pp QoQ
Top 10 Chemicals & Petrochemicals companies on management guidance
See the sector's top 10 — free with your mobile number.
Chemcon Speciality Chemicals Ltd Q4 FY25 key numbers
- Revenue
- YoY PAT for Q4: Rs. 3.9 Crs, up 36% from Rs. 2.9 Crs.
As stated in Chemcon Speciality Chemicals Ltd's Q4 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Chemcon Speciality Chemicals Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY25 Revenue from Operations: Rs. 54.9 Crs, down 8% YoY from Rs. 59.6 Crs in Q4 FY24 (Page 8, 6). Q4 FY25 EBITDA: Rs. 5.8 Cr, up 32% YoY from Rs. 4.4 Cr in Q4 FY24 (Page 8).
From Chemcon Speciality Chemicals Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY25 Revenue from Operations: Rs. 54.9 Crs, down 8% YoY from Rs. 59.6 Crs in Q4 FY24 (Page 8, 6)
- Q4 FY25 Sales Volume:
- Inorganic Chemicals: 1,186 MT (down from 1,314 MT in Q4 FY24)
- Organic Chemicals: 1,024 MT (down from 2,124 MT in Q4 FY24) (Page 6)
- YoY PAT for Q4: Rs. 3.9 Crs, up 36% from Rs. 2.9 Crs (Page 8)
- Outlook:
- Early signs of recovery in demand for some organic chemicals
- New products for import substitution undergoing client approvals and trial dispatches, expected to have commercial potential soon
2 more points from Chemcon Speciality Chemicals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Chemcon Speciality Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planned capacity expansion includes two new manufacturing units: P-10 and P-11 at Manjusar, Gujarat.
- Both units will manufacture organic chemicals.
- Commissioning of P-10 and P-11 units is targeted for the first half of FY26 (H1 FY26).
- These expansions aim to support pharmaceutical applications and diversify product portfolio, aligning with import substitution and growth strategy.
- Two proposed expansion plants are under process, located at Manjusar near Vadodara.
2 more points from Chemcon Speciality Chemicals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Chemcon Speciality Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Chemcon Speciality Chemicals Ltd — Quarterly revenue & net profit
Chemcon Speciality Chemicals Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 55 | 60 | -7.9% | 54 | +0.9% |
| Operating profit (EBITDA) | 6 | 4 | +32.2% | 11 | -48.7% |
| Operating margin | 10.55% | 7.35% | +3.2 pp | 20.76% | -10.2 pp |
| Profit before tax | 5 | 4 | +29.8% | 12 | -54.4% |
| Net profit (PAT) | 4 | 3 | +36.2% | 9 | -55.2% |
| EPS (₹) | 1.08 | 0.79 | +36.7% | 2.41 | -55.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹65 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Chemcon Speciality Chemicals's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Atul (Q4 FY25)
Consolidated revenue from operations for 2024-25: ₹5,583 cr, 18% increase YoY from ₹4,726 cr in 2023-24 (Page 36). Key concall takeaways from Atul Ltd's Q4…
- Vidhi Specialty (Q4 FY25)
109.5 Crs, up 40.2% YoY (from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Valiant Organics (Q4 FY25)
Q4-FY25 revenue from operations (consolidated) was INR 2,038 million, a 15.3% year-on-year (YoY) increase from INR 1,768 million in Q4-FY24 (Page 12 and 10)…
- Clean Science (Q4 FY25)
2,500 crores to Rs. Key concall takeaways from Clean Science's Q4 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Chemcon Speciality Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Chemcon Speciality Chemicals Ltd Q4 FY25 results?
Q4 FY25 Revenue from Operations: Rs. 54.9 Crs, down 8% YoY from Rs. 59.6 Crs in Q4 FY24 (Page 8, 6). Q4 FY25 EBITDA: Rs. 5.8 Cr, up 32% YoY from Rs. 4.4 Cr in Q4 FY24 (Page 8).
What is Chemcon Speciality Chemicals Ltd share price analysis?
Chemcon Speciality Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 28.1 with a market cap of ₹793 Cr. Investors should review the full earnings analysis for detailed insights.
Is Chemcon Speciality Chemicals Ltd planning capital expenditure?
Planned capacity expansion includes two new manufacturing units: P-10 and P-11 at Manjusar, Gujarat.
Keep Chemcon Speciality Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
